A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Not Recruiting

Trial ID: NCT01196208


The purpose of this study is to provide the option of brentuximab vedotin treatment to eligible patients in studies SGN35-005 and C25001

Official Title

An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma

Stanford Investigator(s)

Lauren Maeda
Lauren Maeda

Clinical Associate Professor, Medicine - Oncology


Inclusion Criteria:

   - Participated in either the SGN35-005 or C25001 clinical study and experienced
   progression. Patients who received brentuximab vedotin in C25001 must have had an
   objective response at the time of discontinuation.

   - Completed any previous treatment with radiation, chemotherapy, biologics and/or
   investigational agents at least 4 weeks prior to the first dose of brentuximab vedotin

Exclusion Criteria:

   - History of another primary malignancy that has not been in remission for at least 3

   - Known cerebral/meningeal disease

   - Peripheral neuropathy of grade 2 or greater

   - Females who are pregnant or breastfeeding


drug: brentuximab vedotin

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.